Failure to Identify HIV-Infected Individuals in a Clinical Trial Using a Single HIV Rapid Test for Screening

Conclusions: In clinical trials, HIV infections can be missed for a variety of reasons. Using more than one assay to screen for HIV infection may reduce the number of missed infections. Content Type Journal ArticleCategory Original ArticlePages 62-68DOI 10.1310/hct1502-62Authors Estelle Piwowar-Manning, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MarylandJessica M. Fogel, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MarylandOliver Laeyendecker, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MarylandShauna Wolf, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MarylandVanessa Cummings, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MarylandMark A. Marzinke, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MarylandWilliam Clarke, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MarylandAutumn Breaud, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MarylandSarah Wendel, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MarylandLei Wang, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WashingtonPriscilla Swanson, Infectious Disease Research, Abbott Diagnostics, Abbott Park, IllinoisJohn Hackett,...
Source: HIV Clinical Trials - Category: Infectious Diseases Tags: HIV Clinical Trials Source Type: research